A lipid excipient
Related Products
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

DMG-PEG(2000)

Item No. 33945

Technical Information
Formal Name
α-[(2R)-2,3-bis[(1-oxotetradecyl)oxy]propyl]-ω-methoxy-poly(oxy-1,2-ethanediyl)
CAS Number
160743-62-4
Synonyms
  • 1,2-Dimyristoyl-rac-glycero-3-methoxy-Polyethylene Glycol(2000)
Molecular Formula
(C2H4O)nC32H62O5
Purity
≥90%
MW
2.5 kDa (Average)
A crystalline solid
DMF: 1 mg/mlDMSO: Slightly solubleEthanol: 1 mg/ml
SMILES
COCCOCC(COC(CCCCCCCCCCCCC)=O)OC(CCCCCCCCCCCCC)=O
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Cayman Chemical
    Visit Our Lipid Nanoparticle Resource Center for Additional Tools & Resources
    EXPLORE NOW
    Product Description

    DMG-PEG(2000) is a lipid excipient that has been used in combination with other lipids in the formation of lipid nanoparticles (LNPs).1 Administration of fumarylacetoacetate hydrolase (FAH) mRNA in DMG-PEG(2000)-containing LNPs increases survival in a mouse model of hereditary tyrosinemia type 1 (HT-1). Formulations containing DMG-PEG(2000) have been used in the development of LNPs for the delivery of mRNA-based vaccines.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Cheng, Q., Wei, T., Jia, Y., et alDendrimer-based lipid nanoparticles deliver therapeutic FAH mRNA to normalize liver function and extend survival in a mouse model of hepatorenal tyrosinemia type I. Adv. Mater. 30(52), e1805308 (2018).

    Product Citations

    Peña, Á., Heredero, J., Blandín, B., et alMulticomponent thiolactone-based ionizable lipid screening platform for efficient and tunable mRNA delivery to the lungs. Commun. Chem. 8(1), 116 (2025).

    Mata, E., Broset, E., Matute, C., et alPreserved efficacy of lyophilized SARS-CoV-2 mRNA vaccine incorporating novel ionizable lipids after one year at 25 °C. NPJ Vaccines 10(1), 135 (2025).

    Broset, E., Larraga, A., Lampaya, V., et alA complete approach for circRNA therapeutics from purification to lyophilized delivery using novel ionizable lipids. Int. J. Mol. Sci. 26(11), 5138 (2025).

    Vinales, I., Silva-Espinoza , J.C., Medina, B.A., et alSelective transfection of a transferrin receptor-expressing cell line with DNA-lipid nanoparticles. ACS Omega 9(38), 39533-39545 (2024).

    Yeo, S., Lee, H., Lee, J., et alOptimization of polyethylene glycol shielding and mannose density on the lipid nanoparticles for efficient delivery to macrophages and spleens. Int. J. Pharm. 662, 124540 (2024).